AZN News and Press, AstraZeneca PLC From 04/25/24

Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery AstraZeneca: Revenue and EPS summary Financial performance for Q1 2024 (Growth numbers at CER) Total Revenue up 19% to $12,679m, driven by an 18% increase in Product Sal...

2024-04-24 12:24:57 ET AstraZeneca: What The Market's Missing What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca ...

2024-04-24 04:30:40 ET Summary AstraZeneca's stock has declined by nearly 8% over the past year due to slowing sales of its COVID-19 vaccine. However, the company has a strong pipeline, recent approvals, and a series of acquisitions that offer promising prospects. Analysts pro...

2024-04-24 03:16:41 ET More on Angle Plc, AstraZeneca, etc. What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca Imfinzi l...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

2024-04-21 08:00:00 ET As the market gears up for another eventful earnings week, investors are eagerly anticipating reports from a wide array of companies across various sectors. Big names like Tesla ( NASDAQ: TSLA ), Microsoft ( NASDAQ: MSFT ), Alphabet ( NASDAQ: GOOG ...

2024-04-19 14:48:33 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among ...

2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-04-16 18:08:05 ET According to J.P. Morgan, pricing power is cropping up as a corporate concern in the fledgling first quarter earnings season, with some major European companies flagging the issue during analyst calls.... Read the full article on Seeking Alpha For further ...

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...